Skip to main content

Advertisement

SpringerLink
Log in

Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Osteoprotegerin (OPG), identical with osteoclastogenesis inhibitory factor, is a member of a subgroup of the tumor necrosis factor (TNF)-receptor superfamily, which functions as a soluble decoy receptor. It has been reported that OPG expression is associated with bone metastasis of cancer of the breast and prostate. In the present study, we examined the expression of OPG in gastric carcinomas using immunohistochemistry and reverse-transcription polymerase chain reaction methods, and compared with clinicopathological parameters. The expression of OPG mRNA was confirmed in a gastric carcinoma cell line (MKN-7) and gastric carcinoma tissues. Immunohistochemically, strongly positive staining of OPG was found in 65% (67/103) of gastric carcinomas, whereas OPG protein was not detected in non-neoplastic mucosal epithelia. The expression of OPG protein in gastric carcinoma tissues correlates significantly with depth of tumor invasion, nodal metastases and advanced tumor stage. Furthermore, the prognosis of the cases with strong OPG expression was significantly worse than those with weak or no expression of OPG. These results suggest that OPG may participate in stomach carcinogenesis, invasion and metastasis, and may serve as a novel molecular marker for aggressive gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2. A–D
Fig. 3.

Similar content being viewed by others

References

  1. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL (2001) Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611–616

    Article  CAS  PubMed  Google Scholar 

  2. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268

    CAS  PubMed  Google Scholar 

  3. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363–14367

    CAS  PubMed  Google Scholar 

  4. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine TRAIL. J Exp Med 189:1343–1354

    Article  CAS  PubMed  Google Scholar 

  5. Holen I, Croucher PI, Hamdy FC, Eaton CL (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619–1623

    CAS  PubMed  Google Scholar 

  6. Ito R, Kitadai Y, Kyo E, Yokozaki H, Yasui W, Yamashita U, Nikai H, Tahara E (1993) Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res 53:4102–4106

    CAS  PubMed  Google Scholar 

  7. Japanese Research Society for Gastric Cancer (ed) (1995) Japanese Classification of Gastric Carcinoma, 1st English edn. Kanehara & Co., Ltd, Tokyo, pp 38–65

  8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176

    PubMed  Google Scholar 

  9. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET (2001) Bone metastatic LNCaP-derivative C4–2B prostate cancer cell line mineralizes in vitro. Prostate 47:212–221

    Article  CAS  PubMed  Google Scholar 

  10. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K (2001) Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61:1637–1644

    CAS  PubMed  Google Scholar 

  11. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432–4436

    CAS  PubMed  Google Scholar 

  12. Ochiai A, Yasui W, Tahara E (1985) Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 57:3669–3671

    Google Scholar 

  13. Penno H, Silfversward CJ, Frost A, Brandstrom H, Nilsson O, Ljunggren O (2002) Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. Biochem Biophys Res Commun 293:451–455

    Article  CAS  PubMed  Google Scholar 

  14. Scatena M, Giachelli C (2002) The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med 12:83–88

    Article  CAS  PubMed  Google Scholar 

  15. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319

    PubMed  Google Scholar 

  16. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682

    CAS  PubMed  Google Scholar 

  17. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602

    PubMed  Google Scholar 

  18. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235–1244

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported, in part, by Grants-in-Aid from the Ministry of Education, Culture, Sports, and Technology of Japan, and the Ministry of Health, Labor, and Welfare of Japan. The authors thank Masayoshi Takatani and Mutsumi Ueda for their skillful technical assistance. The authors are also grateful to Noriko Sagawa for her secretarial assistance.

Author information

Authors and Affiliations

  1. Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, Japan

    Reiko Ito, Hirofumi Nakayama, Kazuya Kuraoka, Junichi Motoshita, Naohide Oue & Wataru Yasui

  2. Department of Surgery, Research Institute for Nuclear Medicine and Biology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima , Japan

    Kazuhiro Yoshida

  3. Department of Human Nutrition, Faculty of Human Sciences, Hiroshima Bunkyo Women's University, 1-2-1 Kabe-higashi, Asakita-ku, 731-0295, Hiroshima , Japan

    Noriko Oda

Authors
  1. Reiko Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hirofumi Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuya Kuraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junichi Motoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noriko Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naohide Oue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wataru Yasui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wataru Yasui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ito, R., Nakayama, H., Yoshida, K. et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 443, 146–151 (2003). https://doi.org/10.1007/s00428-003-0845-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-003-0845-8

Keywords

Search

Navigation